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ABSTRACT
Objectives: To determine the prevalence of class A extended spectrum b-lactamases (ESBL)-pro-
ducing Escherichia coli and Klebsiella spp., and to investigate clonality among ESBL-producing iso-
lates of nosocomial and community infections. Methods: The study involved 354 nosocomial infec-
tions samples and 992 community infections samples, obtained between 2003 and 2006 at Caxias 
do Sul, RS. The detection of ESBL was performed by the disk-diffusion test. Presence of blaCTX-M, 
blaSHV and blaTEM b-lactamase genes was evaluated by PCR, and genomic typing was determined by 
pulsed-field gel electrophoresis analysis. Results: Higher frequency of ESBL-producing isolates were 
detected among nosocomial samples of E. coli (6.7%) and Klebsiella (43.7%), than those obtained 
from community infections (0.4% and 2.6%). blaTEM and blaCTX were the most prevalent ESBL gene 
families in both E. coli and Klebsiella isolates. Different pulsotypes were obtained among ESBL-pro-
ducing E. coli and 11 clones for Klebsiella spp., which occurred over the years and in different hos-
pital wards. Among ESBL-producing K. pneumoniae, 74.3% transferred ESBL genes by conjugation 
and exhibited concomitant decreased aminoglycosides susceptibility. Conclusion: ESBL-producing 
E. coli, and especially K. pneumoniae are essentially a nosocomial problem, and their dissemination 
to the community is relatively limited. The great genetic variability observed among ESBL-producing 
bacteria indicates polyclonal spread and high transference of ESBL genes between bacteria in the hos-
pital environment. This information is of paramount importance for nosocomial infection control. 
Keywords: b-lactamases; polymerase chain reaction; bacterial typing techniques.
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INTRODUCTION
Extended-spectrum b-lactamase-producing 
clinical isolates among members of the Entero-
bacteriaceae family, especially Klebsiella pneu-
moniae and Escherichia coli, represent one of 
the most important world problems of b-lac-
tam antimicrobial resistance, commonly used 
in the treatment of many bacterial nosocomial 
and community infections.1 
Traditionally ESBLs appeared just after the 
introduction of third-generation cephalospor-
ins, and evolved from parent enzymes due to 
point mutation in the blaTEM-1/2 and blaSHV-1 
genes around the b-lactamase active site.2 The 
majority of ESBLs belong to the functional 
class 2be/molecular class A, particularly TEM 
and SHV types, and the CTX-M family b-lac-
tamases encoded by genes captured by mobile 
elements from the chromosomes of the envi-
ronmental bacteria Kluyvera spp.1
At present, the definition of ESBL as 2be/
molecular class A, clavulanic acid inhibited 
enzymes that cause resistance to penicillins, 
to all cephalosporin generations, and to the 
monobactam aztreonam, but not to cephamy-
cins or carbapenems, is narrow and excludes 
other clinically important acquired b-lacta-
mase with wider spectrum.1 In the effort to 
prevent the spread of acquired b-lactamase, 
a new classification had been proposed in-
cluding b-lactamase with activity against 
extended-spectrum cephalosporins and/or 
carbapenems, making the classification more 
accessible to clinicians, infection control 
professionals, hospital managers, and politi-
cians. Three groups of ESBL were projected: 
(1) ESBLA (classical class A ESBLs); (2) ESBLM 
(plasmid-mediated AmpC and OXA-ESBLs 
classedw as miscellaneous ESBLs); and (3) 
ESBLCARBA (carbapenemases).1,3
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The correct identification of ESBL-producing bacte-
ria has important clinical-epidemiological and laboratory 
implications. First, patients may experience a delay in ap-
propriate treatment if ESBL-producing bacteria are not 
correctly detected by routine antimicrobial susceptibility 
tests.4 Second, while carbapenemics are the most effective 
therapy for ESBL bacterial infections, their routine use can 
select resistant strains, as the emergence of imipenem-re-
sistant Acinetobacter baumanii, Pseudomonas aeruginosa 
and K. pneumoniae.5,6 Third, ESBL genes are located on 
large plasmids that can harbor genes for resistance to other 
non-b-lactams antibiotics, and therefore, ESBL-producing 
bacteria often exhibit multidrug-resistant phenotypes, re-
ducing the drug arsenal even further.1 Fourth, genes encod-
ing ESBLs are typically located in conjugative plasmids or 
integron-like structures and can be effectively transferred 
to other strains and species.7,8 Finally, ESBL-producing or-
ganisms, especially K. pneumoniae, but also E. coli, have 
been responsible for serious nosocomial infection out-
breaks that lead to prolonged hospital stay, increased mor-
bidity and mortality, and consequently increase healthcare 
associated costs.9-11 
Since the first description of ESBL in 1983, in Germa-
ny, ESBL-producing clinical isolates have spread rapidly 
throughout Europe and the United States and are now dis-
seminated worldwide.12,13 However, the world prevalence of 
ESBL producers varies greatly, even among health institu-
tions in the same country.14 Although it is a major threat for 
patients in the hospital, currently ESBL are becoming an 
emerging problem for patients in long-term care facilities, 
and also in the community in some areas of the world.15-17
The aims of this study were to determine the prevalence 
of ESBL among E. coli and Klebsiella spp. in Caxias do Sul, 
in the southern region of Brazil, to identify the prevalence of 
b-lactamase genes (blaTEM, blaSHV and blaCTX-M), and to inves-
tigate clonality among clinical isolates of ESBL-producing 
E. coli and Klebsiella spp. of nosocomial and community in-
fections during a period of three years. 
MATERIAL AND METHODS
Patient population and definitions 
The study was carried between April 2003 and May 2006 at a 
private clinical analyses laboratory, and at the General Hos-
pital of Caxias do Sul (HG), located in Rio Grande do Sul 
State Brazil. The HG is a 257-bed public university teaching 
hospital and acts as a referral hospital for a wider area of 
Northeast RS, covering a population of about one million 
inhabitants. Personal data (age, sex), type of specimens, and 
the hospital ward at the HG where the patient had been as-
signed were obtained. Nosocomial infection was defined as 
infection which occurred more than 48 hours after hospital 
admission; infection which occurred less than 48 hours af-
ter hospital admission, if that patient had been hospitalized 
within the prior 30 days; or infection which occurred in a 
patient transferred from another hospital or from a nursing 
home.18 Patients with community infection were those pre-
senting it at a community clinical analyses laboratory and 
those who had a positive culture at the time of or within 
48 hours of hospitalization; in both cases, patients had no 
previous contacts with hospitals or long-term care facility in 
the previous two weeks.19
Bacterial isolates
Clinical specimens obtained from patients with nosocomial 
infection yielded 354 isolates (209 E. coli, 142 K. pneumo-
niae and 3 K. oxytoca), and a total of 992 isolates (953 E. 
coli, 38 K. pneumoniae and 1 K. oxytoca) were obtained from 
patients with community infection. Isolates were identified 
using the conventional biochemical tests and stored at -70°C 
in skim milk. Only one isolate from each patient was includ-
ed in the study.
Screening and confirmation tests of ESBLs 
ESBL-producing isolates identification was made by the 
disk-diffusion screening test with aztreonam, cefotaxime, 
ceftazidime, ceftriaxone, and cefpodoxime, followed by a 
confirmatory test with ceftazidime and cefotaxime, com-
bined with clavulanic acid as recommended by the Clinical 
and Laboratory Standards Institute (CLSI).20 An additional 
confirmatory test was performed with cefepime and cef-
podoxime discs containing clavulanic acid. All the tests 
were conducted with Oxoid antibiotic discs. The stand-
ard strains E. coli ATCC 25922 and K. pneumoniae ATCC 
700603 were used as negative and positive controls of 
ESBLs production.
PCR amplification for detection of b-lactamase 
genes
The bacterial isolates with confirmed ESBL phenotype were 
submitted to PCR assay to identify blaCTX-M, blaSHV and 
bla TEM b-lactamase genes, using the primers and method 
described by Paterson et al.14 The K. pneumoniae ATCC 
700603 strain was used as a positive control for the blaSHV 
gene. 
Molecular typing
Genomic typing of ESBL producing isolates was performed 
by the pulsed-field gel electrophoresis (PFGE) technique 
based on PulseNet PFGE protocol.21 Briefly, genomic DNA 
was prepared in agarose plugs, cut with restriction endonu-
clease SpeI (Invitrogen), and restriction fragments separat-
ed using a CHEF-DRIII system (Bio-Rad). Photographs of 
ethidium bromide-stained gels were examined visually and 
the macrorestriction patterns were interpreted according 
to the criteria proposed by Tenover et al.22 A 48.5 Kb bacte-
riophage λ ladder was used as a DNA size marker.
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Gene transfer assays
Conjugation assays were carried out by a broth mating proce-
dure in Lurian-Bertani (LB) broth with 35 ESBL-producing 
K. pneumoniae isolates susceptible to streptomycin and ceftri-
axone. DH5α E. coli (streptomycin resistant, lactose fermen-
tation negative, and plasmid free) was used as the recipient.23 
Overnight cultures of donor and recipient strains grown in LB 
broth were added to 8 mL of fresh LB broth at a donor-recipient 
ratio of 1:1 (300 μL of cultures each), and incubated for 4 hours 
at 37°C. The mixed culture was plated onto MacConkey agar 
containing 30 μg/mL of ceftriaxone and 300 μg/mL of strepto-
mycin. Six colonies growing on the selections plates and again 
on subculture on selective MacConkey agar were subjected to 
confirmatory tests of ESBLs and to antimicrobial susceptibil-
ity by disk diffusion assays according to CLSI recommendation 
with amikacin, gentamicin, tobramicin, ciprofloxacin, gatiflox-
acin, nitrofurantoin, trimethoprim/sulfamethoxazole and chlo-
ramphenicol. Resistance was considered nontransferable when 
the isolates failed to transfer in more than two experiments. 
RESULTS
Prevalence of ESBL isolates
A total of 1,346 non-replicated isolates (354 from nosocomial 
and 992 from community infection patients) were analyzed. 
Overall, 21.8% (77/354) and 0.5% (5/992) of the isolates were 
confirmed as ESBL producers by the clavulanic acid inhibition 
disk diffusion assay. Fourteen (6.7%) of 209 patients with E. coli 
infection had ESBL-producing strain, compared with 4 (0.4%) 
of 953 patients with community-acquired E. coli infection. ES-
BL-producing K. pneumoniae were isolated from 62 (43.7%) of 
142 patients with nosocomial infection, and from one (2.6%) 
of 38 isolates with community-acquired infection. Among the 
four K. oxytoca isolates, one obtained from a nosocomial pa-
tient exhibited ESBL phenotype (Table 1). 
Patient population and source of specimens 
Of the 1,346 patients studied, the mean age and gender of 
patients with nosocomial infection were different among 
those with community infections (51.4 ± 28.0 years and 
54.8% female versus 39.1 ± 22.4 years and 89.3% female). In 
both patient populations, the most frequent source of infec-
tion was urinary. The high frequency of urinary infections 
(97.7%) among community patients explains the difference 
on gender proportion. The mean age of the patients with no-
socomial infection due to ESBL-producing E. coli and Kleb-
siella spp. differed significantly (40.7 ± 31.7 years, range: 8.3 
months to 88 years versus 4.8 ± 2.9 years, range: 4 days to 92 
years), respectively. Most patients (65.1%) with nosocomial 
infection due to ESBL-producing Klebsiella spp. were male, 
while no gender difference was observed among community 
infection patients. 
The ESBL-producing bacteria obtained from patients with 
nosocomial infections were isolated from the urinary tract 
(5.8% E. coli and 49% Klebsiella spp.), respiratory tract (14.3% 
E. coli and 41.9% Klebsiella spp.), blood/catheter (12.5% E. coli 
and 48.4% Klebsiella spp.), peritoneal liquid (25% Klebsiella 
spp.), and skin/soft tissue (25% Klebsiella spp.). Most ESBL-
producers were detected on patients hospitalized in Intensive-
Care Units, including the Neonatal, Pediatric and Adult ICUs 
(15.9% E. coli and 51.7% Klebsiella spp.), in Clinical-Surgical 
Units (4.3% E. coli and 45.5% Klebsiella spp.), and Urgency 
and Emergency wards (31.6% Klebsiella spp.). 
Prevalence of b-lactamase genes and genotyping
As shown in Figure 1, 61.1% of ESBL-producing E. coli 
were isolated during 2005 to 2006, whereas 67.2% of 
ESBL Klebsiella spp. isolates were collected between 
2003 to 2004. 
The PCR assay allowed detection of blaTEM gene family 
in 66.7% of the isolates of ESBL-producing E. coli, fol-
lowed by blaCTX-M gene (50%) and the blaSHV gene (11.1%) 
(Figure 1A). Several E. coli isolates exhibited b-lactamase 
gene combinations (blaCTX-M and blaSHV, blaCTX-M and 
blaTEM), and no amplification products were observed 
in one ESBL isolate. Among Klebsiella spp. with ESBL-
phenotype, blaTEM gene was the most prevalent (95.3%), 
followed by the blaCTX-M (82.8%), and the blaSHV gene 
(42.2%) (Figure 1B). Combination of two and three ESBL 
genes was detected in 59.4% and 31.3% of ESBL-produc-
ing Klebsiella isolates. 
The clonal relatedness was studied by PFGE. Eight-
een different pulsotypes were obtained among 18 ESBL-
producing E. coli isolates, and 23 pulsotypes among 63 
ESBL-producing K. pneumoniae (Figure 1). One isolate 
was consistently untypeable by the applied method. 
Genotyping revealed that 82.3% of K. pneumoniae 
isolated were non-unique and could be separated into 
11 clones. The most prevalent (Clone 5) with 13 isolates, 
Table 1. Prevalence of ESBL-positive Escherichia coli 
and Klebsiella spp. by origin of the infection
Origin in Total no.      ESBL positive isolates 
infection of isolates No. of % in 
species (n = 1,346) isolates species
Nosocomial 
 E. coli 209 14 6.7 
 K. pneumoniae 142 62 43.7 
 K. oxytoca 3 1 33.3 
Total 354 77 21.8
Community 
 E. coli 953 4 0.4 
 K. pneumoniae 38 1 2.6 
 K. oxytoca 1 0 0 
Total 992 5 0.5
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emerged in 2003 with four isolates in two hospital wards 
(Clinical-Surgical floor 5 and Adult ICU floor 3), and 
was detected again in 2004, with 9 isolates recovered 
from the same hospital wards. The occurrence of differ-
ent clones over the years and hospital wards are shown 
in Table 2.
Table 2. Distribution of the 11 clones of ESBL-producing Klebsiella pneumoniae by genes of ß-lactamases, time 
of detection the isolates and hospital ward
PFGE Nº of    b-lacmatase genes profilea Time (yr) Hospital ward of isolation   Floor 
type isolates CTX-M TEM SHV of isolation (No. of isolates)
Clone 1 4 + + - 2003 Clinical-surgical (1) 6o 
  + + + 2003/2005 Clinical-surgical (1)/b 6o 
  - + + 2006 Adult ICU (1) 3o
Clone 2 6 + + - 2003 Neonatal ICU (2), clinical-surgical (2) 3o, 6o 
  + + - 2003 Urgency-emergency (1), clinical-surgical (1) 1o, 5o
Clone 3 5 + + - 2003 Neonatal ICU (2), adult ICU (1) 3o 
  + + - 2003 Pediatric ICU (1), clinical-surgical (1) 4o, 6o
Clone 4 5 + - - 2003 Pediatric ICU (1) 4o 
  + + - 2003/2004 Clinical-surgical (1), adult ICU (1)/ pediatric ICU (2) 6o, 3o, 4o
Clone 5 13 - + - 2003 Clinical-surgical (1) 5o 
  + + + 2003 Adult ICU (3) 3o 
  + + + 2004 Adult ICU (3)/ clinical-surgical (2) 3o/5o, 6o 
  - + + 2004 Adult ICU (2)/ clinical-surgical (2) 3o/5o, 6o
Clone 6 2 + + + 2003/2004 Adult ICU (2) 3o
Clone 7 5 + + + 2005 Pediatric ICU (1) 4o 
  + - - 2005 Adult ICU (2) 3o 
  + + + 2005 Neonatal ICU (1), adult ICU (1) 3o
Clone 8 2 + + - 2005 Adult ICU (1), pediatric ICU (1) 3o, 4o
Clone 9 2 + + + 2005 Urgency-emergency (1) 1o 
  - + + 2005 Clinical-surgical (1) 5o
Clone 10 3 + + - 2006 Clinical-surgical (1) 6o 
  + + + 2006 Clinical-surgical (2) 6o
Clone 11 4 + + - 2006 Clinical-surgical (2) 5o, 6o 
  - + - 2006 Clinical-surgical (2) 6o
a-, absence; +, presence; b, community infection. Adult ICU, Adult intensive-care unit; Neonatal ICU, Neonatal intensive-care unit;  
Pediatric ICU, Pediatric intensive-care. 
Figure 1: Distribution of different b-lactamase genes among ESBL-positive 18 E. coli (A) and 64 Klebsiella spp. (B) isolates from   
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Among the 35 ESBL-producing K. pneumoniae isolates se-
lected for conjugation experiments, 74.3% (26 isolates) trans-
ferred ESBL genes by conjugation. All donor strains harbored 
the blaCTX-M gene. The transconjugants obtained exhibited de-




Although, in our study, E. coli was more frequently 
isolated than K. pneumoniae, ESBL production was more 
prevalent in K. pneumoniae, with a high prevalence (43.7%) 
in the hospital environment, and especially in pediatric pa-
tients from the neonatal ICU. The high frequency of ESBL-
producing bacteria in ICUs is expected due the great selec-
tive pressure resulting from the large use of antibiotics on 
ICU patients. High prevalence of ESBL among isolated K. 
pneumoniae had been detected in numerous studies as re-
viewed by Paterson and Bonomo.1 However, the prevalence 
of ESBL-positive K. pneumoniae and E. coli varies greatly 
among different geographical areas, with one of the highest 
reported rate (K. pneumoniae 30% to 60%, E. coli 4.5% to 
12%) in Latin American countries, including Brazil.24,25 
As previously reported in Juiz de Fora, Brazil,26 low 
prevalence of ESBL phenotype was detected in community 
isolates, independently of the bacteria species, 2.6% for K. 
pneumoniae and 0.4% for E. coli. Moreover, two of the five 
community-acquired cases reported healthcare contact (un-
dergoing chemotherapy on day hospital) and may be health-
care associated infections. 
Although the clinical impact of ESBLs is related to a com-
bination of factors that rely more heavily on functional rather 
than structural characteristics, in terms of epidemiology or 
long-term effects of antibiotic use, identification of specific 
b-lactamases and/or their genes can play an important role. 
Among ESLB gene families, blaTEM was the most prevalent in 
both E. coli and K. pneumoniae ESBL-producing isolates ob-
tained from nosocomial and community infections. A very 
high prevalence of blaCTX-M (82.8%) was also detected among 
K. pneumoniae isolates, and blaSHV was present in 42.2% and 
11.1% of K. pneumoniae and E. coli ESBL-producing isolates, 
respectively. blaTEM family genes are frequent among entero-
bacteria,1 but not all TEM enzymes can be considered ESBL, 
and sequencing is therefore necessary for allele identifica-
tion.13 Extra-intestinal infections caused by E. coli harbouring 
plasmid-encoded blaCTX-M have been increasingly reported 
worldwide, from both developed and developing countries 
in the last decades.1,15,27-30 Moreover, while most of the SHV 
b-lactamases are ESBLs, it is known that the chromosomic 
blaSHV-1 is highly prevalent in K. pneumoniae.14
Genotyping using PFGE analysis of ESBL-producing K. 
pneumoniae revealed 23 different pulsotypes, consisting of 
11 clones and 12 single patterns. Of the 11 clones, clone 5 
was predominant and a persistent endemic clone in differ-
ent wards and throughout the years. While multiclonal dis-
semination of ESBL-producing K. pneumoniae was found, 
no clonal dissemination of ESBL-producing E. coli was ob-
served. Clonal dissemination suggests cross-transmission, 
which implies adopting precautionary measures of contact, 
including wearing aprons and gloves for contact with the 
colonized or infected patient, together with an efficient hy-
gienization and antisepsis. Alternatively, the great genomic 
variability suggests strong selective pressure on bacterial 
populations, indicating the necessity of proper management 
of antibiotic therapy, particularly within healthcare units. 
CONCLUSION
To sum up, the data obtained in this study showed 
that ESBL-producing isolates of E. coli and especially 
of Klebsiella spp. are essentially a nosocomial problem, and 
their dissemination to the community are not very signifi-
cant. However, public health professionals must remain alert 
to the advancing issues associated with ESBLs to assist po-
tential healthcare-associated and community outbreaks.
Genes blaTEM, blaCTX-M, and blaSHV were detected in high 
frequency among ESBL-positive K. pneumoniae and E. coli 
isolates, occurring alone or in combination. The high preva-
lence of ESBL genes that are frequently found in conjugative 
plasmids and/or integrons may be considered a risk factor 
as they can be efficiently transferred within and between en-
terobacterial species. 
Moreover, it was observed a great genomic variability in 
the ESBL-producing isolates of E. coli and Klebsiella spp., in-
dicating a strong selective pressure of antimicrobials. How-
ever, it was also found that the polyclonal spread of strains 
might contribute to the proliferation of ESBL K. pneumo-
niae in the hospital and that endemic ESBL clone persisted 
throughout the years in the hospital. Finally, we have shown 
that molecular typing ESBL-producing K. pneumoniae was 
clinically relevant, given that patient-to-patient transmis-
sion of organisms harboring ESBLs, which were fundamen-
tal for infection control interventions, clearly occurs. 
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